May 20th 2024
"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Olaparib/abiraterone combo approved in European Union for mCRPC
December 21st 2022The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
FDA delays decision on olaparib/abiraterone combo for mCRPC
December 15th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
December 13th 2022“One of the things that drives me to be a part of advanced prostate cancer care is that literally every 6 months, we are having major trials read out guideline-based changes in care,” says Jason Hafron, MD.
A Look Into The Future of PSMA-Targeted Therapies in Prostate Cancer
December 12th 2022Panelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.
Darolutamide now available in England for mHSPC
November 29th 2022Approval of the treatment was based on the placebo-controlled phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT and docetaxel boosted overall survival versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Concurrent/adjuvant ADT sequencing appears optimal in patients receiving prostate-only RT
November 22nd 2022“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.
Sequencing of Conventional and PSMA-PET Imaging in Prostate Cancer
November 21st 2022Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.